Markets
BSE See NSE See 39,337.51
224.77 (0.57%)
collapse Related Readings collapse

Hot Chips - Stock recommendations for your portfolio

| 2/9/2012 9:30 PM Thursday

IPCA LABORATORIES | BSE Code: 524494 | Volume: 2438 | CMP: Rs 320

Ipca Laboratories has performed well for Q3 FY12. Its export formulations business grew by 73 per cent on the back of strong growth in the anti-malarial, generic and the promotional business segments. The domestic formulations business, however, grew at a lower rate of six per cent on a YoY basis. The gross and EBITDA margins improved by 235 basis points and 550 basis points respectively. The Indore SEZ facility was inspected by the USFDA in January 2012 without
any adverse observations. The USFDA approval may trigger five-six ANDA approvals for the company. This facility is expected to have a peak revenue potential of Rs 400 crore over the next two-three years. In addition to this, the management has provided guidance for 15 per cent growth in the domestic business in Q4 FY12. The operating margins are expected to improve once the additional field force becomes productive going forward. Investors can look at the scrip from a medium-term perspective.

Last Seven Days Volume Table
  (No. of Shares)
DaysVolume
31-Jan-12 47409
1-Feb-12 103998
2-Feb-12 24158
3-Feb-12 15344
6-Feb-12 5479
7-Feb-12 109959
8-Feb-12 2438

DR. REDDY'S LABORATORIES | BSE Code: 500124 | Volume: 29000 | CMP: Rs 1620

The company’s results for Q3 FY12 have been good, beating the street’s expectations by substantial margins. This was primarily driven by a higher-than-expected upside from Zyprexa, which contributed USD 99 million to the Q3 FY12
revenues. Excluding this, the overall revenues and those from the US grew by 22 per cent and 40 per cent respectively.
It is expected that a steady stream of limited competition launches in the US market along with healthy trends in Russia/CIS and APIs are likely to keep the earnings visibility clear for the next four-five quarters. With a strong US
pipeline, as also better performance by the US OTC business in 9M FY12, the growth momentum is likely to continue
going forward too. Fondaparinux filing for EU in FY13 and the finalisation of the Fujifilm agreement are under discussion,
which may act as triggers going forward. Investors can look at the scrip from a medium-term perspective.

Last Seven Days' Volume Table
  (No. of Shares)
DaysVolume
31-Jan-12 17202
1-Feb-12 7619
2-Feb-12 29069
3-Feb-12 217855
6-Feb-12 75914
7-Feb-12 20131
8-Feb-12 29000

Disclaimer: The scrips in this column have been recommended with a short-term investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations.

 

Find More Articles on: DSIJ Magazine, Hot Chips, Stock Recommendations, Fundamental Picks, Product, Large Cap

news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »

DSIJ Mindshare

12345678910Last

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Logistics sector will play a vital role in making the concept of ‘Make in India’ a success. This will be further aided by some of the recent steps taken by Government of India such as granting of infra sector status to logistics sector.

Best and worst Performing Sector Funds of Year 2017

Best and worst Performing Sector Funds of Year 2017

As the year-end has approached most of you are eager to know the mutual fund movers and shakers of the year 2017. Read on to find the performance of various sector dedicated funds.

Markets may start positive, but volatility likely due to F&O expiry

Markets may start positive, but volatility likely due to F&O expiry

The start of the F&O expiry day is likely to be in the green, but volatility may creep in with the progress of the session. The SGX Nifty suggests that the Nifty could open at 10,525 with gains of 32 points at the opening bell. 

Pidilite announces buyback of Rs 500 crore

Pidilite announces buyback of Rs 500 crore

The buyback offer comprises purchase of up to 50,00,000 equity shares. The buyback offer size comprises 0.975 per cent of the total paid-up equity capital of the company.

Bank Nifty drags markets to close in the red

Bank Nifty drags markets to close in the red

The late session fall in Bank Nifty changed the direction of the market, leading to a marginal fall in the benchmark indices. Bank Nifty yet again resisted at its multiple point downward sloping trendline level at 25733.

Six major underperforming MF schemes having higher expense ratios

Six major underperforming MF schemes having higher expense ratios

Mutual funds with a large size of assets under management (AUMs) are supposed to have lower expense ratios. However, there are schemes with large AUMs but having higher expense ratios and generating lower returns. 

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma index has come in as the healer in an otherwise sluggish market. Index has given a consolidation breakout at the 9420 level today and if the it sustains 9420, followed by 9628 on the upside, it has a long way to go.

Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Following stocks are close to their 52-week low as at 12.35 p.m. on December 27.

Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

The markets on December 27 opened gap down. BSE Sensex is trading at 34,068.15, up by 57.54 points and the Nifty is trading at 10,539.45, up by 7.95 points.

Five stocks with selling interest

Five stocks with selling interest

Overall volumes in futures & options currently stand at 62.75 lakh contracts with a turnover of Rs. 5,19,204.72 crore.